Press Detail

PRESS RELEASE

Biotest AG: Annual general meeting approves increase of dividend and a share split

- Dividend payment of EUR 0.60 per ordinary share and EUR 0.66 per preference share

- Share split with the relation of one to three approved

Dreieich/ Frankfurt a. M., 7 May 2015. At the annual general meeting (AGM) held on 7 May 2015 in Frankfurt am Main, shareholders of Biotest AG approved the payment of an increased dividend. With 77,54 percent of the ordinary share capital represented at the meeting, a payment of EUR 0.60 per ordinary share and EUR 0.66 per preference share was resolved with a high degree of approval. The amount of dividends paid increased by 5%. The overall dividend payment will amount to EUR 8.3 million.

The annual general meeting attended by 203 shareholders formally discharged the members of the Management Board and Supervisory Board for financial year 2014. The annual general meeting also approved the capital increase from capital funds and a share split with the relation of one to three as well as the required amendment of the articles of association.

The full text of the address given by Dr. Bernhard Ehmer at the AGM is available at: http://www.biotest.com/de/en/investor_relations/shareholders_meeting.cfm

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2.100 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart